

Curriculum Vitae

Name: **Mujeeb U. Shad, M.D., M.S.C.S.**

Home Address 779 Etter Creek Street, Las Vegas, NV 89138

Office Address 5400 South Rainbow Boulevard
Las Vegas, NV 89118
Tel. # (832) 506-5201
E-Mail: mujeeb.shad@uhsinc.com
E-Mail: mujeebushad@gmail.com

Sex Male

Marital Status Married

Immigration Status US Citizen

NPI 1871519041

EDUCATION:

Masters of Science
In Clinical Sciences
(MSCS.) Fall, 2007

Department of Clinical Sciences (DCS), University
of Texas Southwestern School of Medicine Dallas.

Internship & Residency Training

July 1996 - June 1998

Fellow in Psychopharmacology, Psychiatric Research
Institute, University of Kansas School of
Medicine-Wichita.

July 1993 - June 1996

Psychiatry Intern & Resident, University
of Kansas School of Medicine-Wichita, Kansas.

Medical Graduation

MBBS. Bachelor of Medicine and Surgery, Sind Medical
College, University of Karachi, Pakistan, June 25, 1983.

Premedical

DJ, Sind Government College, Karachi, Pakistan 1975.

High School Marie Colaco School, Karachi, 1973.

EMPLOYMENT HISTORY: The primary affiliations are bolded.

January 2021 – Present	Adjunct Professor of Psychiatry, University of Nevada Las Vegas, Nevada.
September 2020 – Present	Adjunct Professor of Psychiatry, Touro University Nevada, Las Vegas, NV
August 2020 – Present	Residency Program director, Valley Health System, Las Vegas, NV.
February 2020 – August 2020	Adjunct Professor, Touro University, Vallejo, California.
May 2020 – August 2020	Co-Chair Continuing Medical Education (CME) committee, Napa State Hospital, California.
January 2020 – August 2020	Staff Psychiatrist, Napa State Hospital, Napa, California.
June 2016 – January 2020	Research and Clinical supervisor for psychiatry residents at the Good Samaritan Mental Healthcare Residency Training Program in Corvallis, Oregon.
July 2019 – November 2019	Professor of Psychiatry Oregon Health & Science University, Portland.
March 2014 – August 2017	Site Residency Director at the Oregon State Hospital for psychiatry residents from Oregon Health & Science University.
March 2014 – December 2018	Supervising Psychiatrist, Oregon State Hospital, Salem, Oregon.
April 2014 – February 2017	Chair for the Medical and Allied Health Professional Staff (MAHPS.) Graduate Medical Education Committee for 2014 & 2015 and Supervising Psychiatrist, Oregon State Hospital, Salem Oregon.
March 2014 – June 2019	Associate Professor of Psychiatry Oregon Health & Science University, Portland.

Curriculum Vitae

Mujeeb U. Shad, M.D., M.S.C.S

- November 2013 – February 2014 Staff Psychiatrist at Coalinga State Hospital, Coalinga, California.
- April 2013 – September 2013** Residency Program Director and Associate Professor Department of Psychiatry, Southern Illinois University Springfield Illinois.
- October 2012 – March 2013 Director of the Outpatient Research Clinic for Psychotic Disorders Schizophrenia Research Division Department of Psychiatry, The University of Texas Medical School at Houston, Texas Medical Center, Houston, Texas.
- July 2012 – March 2013 Attending, Competency Restoration Unit at the Harris County Psychiatric Center, Department of Psychiatry, University of Texas Health Sciences Center at Houston, Texas Medical Center, Houston, Texas.
- July 2010 – March 2013** Associate Professor, Department of Psychiatry, University of Texas Medical School at Houston, Texas Medical Center, Houston, Texas.
- September 2007 – January 2008 Staff Psychiatrist, North Texas VA Healthcare System, Medical Center Dallas, Texas.
- August 2004 – August 2007 Medical Director, Schizophrenia Outpatient Research Clinic and Deputy Director of Stanley Center for Early Drug Development, The Division of Translational Research in Schizophrenia, Department of Psychiatry, University of Texas Southwestern Medical School, Dallas, Texas.
- August 2004 – June 2010** Assistant Professor, Department of Psychiatry, the University of Texas Southwestern at Dallas, Texas.
- January 2004 – August 2004 Inpatient attending for Sigma (Schizophrenia) Team at VA Healthcare System, Highland Drive, Pittsburgh PA.
- March 2002 – December 2003 Research Physician with Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) at Bellefield Clinic, Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania.

Curriculum Vitae

Mujeeb U. Shad, M.D., M.S.C.S

- May 2001 – March 2002 Medical Director, Outpatient Care at Comprehensive Care Services (CCS); Department of Psychiatry (Western Psychiatric Institute and Clinic) University of Pittsburgh School of Medicine-Pittsburgh, Pennsylvania
- July 2000 – August 2004** Assistant Professor, Department of Psychiatry (Western Psychiatric Institute and Clinic), University of Pittsburgh School of Medicine-Pittsburgh, Pennsylvania.
- July 1998 – June 2000** Assistant Professor, Department of Psychiatry, University of Kansas School of Medicine-Wichita.
- March 1999 – June 2000 Director, Outpatient Services, Department of Psychiatry, University of Kansas School of Medicine-Wichita.
- July 1998 – February 1999 Associate Director, Outpatient Psychiatry Services, Department of Psychiatry, University of Kansas School of Medicine-Wichita.
- July 1996 - June 1998 Fellow in Psychopharmacology, Psychiatric Research Institute, University of Kansas School of Medicine-Wichita.
- July 1993 - June 1996 Psychiatry Resident, University of Kansas School of Medicine-Wichita, Kansas.
- January 1992 - June 1993 Research Fellow in the Anxiety and Depression Clinic, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York.
- January 1991 - December 1991 Research Assistant in the Schizophrenia Clinic, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York.
- January 1990 – December 1990 Instructor in the Department of Anatomy, Aga Khan Medical University, Karachi, Pakistan.
- November 1986 - December 1989 Demonstrator in the Department of Anatomy, Sind Medical College, Karachi, Pakistan.
- September 1985 - October 1986 Medical Officer in Lyari General Hospital, Karachi, Pakistan.

Curriculum Vitae
Mujeeb U. Shad, M.D., M.S.C.S

July 1984 - August 1985	Medical Officer at a sub-rural health center, Begna Mori, Sind Pakistan.
July 1983 - June 1984	House Surgeon, Jinnah Hospital and Postgraduate Medical Center, Karachi, Pakistan

UNDER REVIEW PUBLICATIONS:

1. **Mujeeb U. Shad**, Kristen Sioson, Asif H. Khan, MD, Kiran Khalid, Obiora Onwuameze, Ira Glick. Problem-based learning in psychopharmacology. Submitted to Academic Psychiatry January 2022.
2. Hamid Bateni, Elham Soltani, Kishwar Ali, **Mujeeb U. Shad**. Effect of TMS therapy on postural control of individuals with major depressive disorder, a pilot study. Submitted to Brain Stimulation, January 2022.
3. Shahzain H, **Shad MU**. Diagnosis and management of major depressive disorder in primary care clinics in Karachi, Pakistan. Submitted to Asian Journal of Psychiatry 2022.

PEER-REVIEWED PUBLICATIONS:

1. **Mujeeb Shad**. High-Dose Therapy in Treatment-Refractory Psychosis. A Retrospective Study. Accepted to publish in the Primary Care Companion for CNS Disorders December 2022.
2. Elham Soltani, Hamid Bateni, **Mujeeb U. Shad**. Different modalities of transcranial magnetic stimulation to manage schizophrenia. Accepted by Primary Care Companion for CNS Disorders Jan 2022.
3. **Mujeeb U. Shad**. Acute Aggression after Progesterone Discontinuation in a Young Female: A Case report. Prim Care Companion CNS Disord 2022;24(1):21cr02932
4. Sana Javed, **Mujeeb U. Shad**. COVID-Related Psychosis in Adolescents: A Case-Based Review. In press Primary Care Companion for CNS Disorders, December 2021.

5. **Mujeeb U. Shad.** Therapeutic clozapine monitoring to reduce long-term hospitalization in a patient with clozapine-resistant schizophrenia. In press, *Psychiatric Annals*, July 2021.
6. Bennett, S., Shad, M.U. Valproic acid autoinduction: a case-based review. *Int J Bipolar Disorder* **9**, 27 (September 2021). <https://doi.org/10.1186/s40345-021-00232-6>.
7. **Mujeeb U. Shad.** Genetic Testing for Antipsychotic Pharmacotherapy. Published online by Encyclopedia. July 26, 2021. <https://encyclopedia.pub/13520>.
8. **Mujeeb U. Shad.** "Genetic Testing for Antipsychotic pharmacotherapy: Bench to Bedside. *Behav. Sci.* **2021**, *11*, 97. <https://doi.org/10.3390/bs11070097>.
9. **Mujeeb Shad.** Is High-Dose Maintenance Therapy Effective in Treatment-Refractory Psychosis? *Schizophr Res.* 2021; 229:38-44.
10. Grant Meredith, Michael DeLollis, **Mujeeb U. Shad.** Potential Treatment for Overdose with Synthetic Cannabinoids. *Med Cannabis Cannabinoids.* March 2020. <https://doi.org/10.1159/000506635>.
11. Wagner A, **Shad MU.** Relationship between clozapine levels and acute inflammatory stress **The Primary Care Companion for CNS. Disorders**, July 1, 2020, 22(4). DOI: [10.4088/pcc.19br02586](https://doi.org/10.4088/pcc.19br02586) PMID: 32628372.
12. Yeager, A., **Shad, MU.** "Can aripiprazole be used to manage antipsychotic-induced hyperprolactinemia? A retrospective case series," *Prim Care Companion CNS. Disord.* 2020; 22(1):19br02536. DOI: [10.4088/pcc.19br02536](https://doi.org/10.4088/pcc.19br02536) PMID: 31999895
13. **Shad, M. U.** (2020). Is there an association between anxiety symptoms and valsartan treatment? *Journal of Affective Disorders*, *261*, 111-112. <https://doi.org/10.1016/j.jad.2019.10.004>.
14. Chiu S, Farina MW, Terpstra K, Badmaev V, Cernovsky Z, Bureau Y, Raheb H, Husni M, Copen J, **Shad M**, Jirui H, Campbell R, Khazaeipool Z, Carriere A (2019). Exploratory Study of Curcumin isolated from Turmeric *Curcuma Longa*, the Putative Histone Deacetylase Inhibitor, as added-on strategy to antipsychotics in

- treating negative symptoms and Neuro-cognitive deficits in Schizophrenia; *Advance Research Journal of Multidisciplinary Discoveries*; 40(2) pp. 06-15
15. **Shad MU**, Felzien, E., Roy, K., & Sethi, S. (2020). How to identify and manage non-response to clozapine? *Asian Journal of Psychiatry*, 45, 50-52. <https://doi.org/10.1016/j.ajp.2019.08.016>.
 16. **Shad, MU**, Howard, L, Kristopher T, Ag V. Right temporal variant frontotemporal dementia misdiagnosed as schizophrenia. *Current Psychiatry Research and Reviews*. Volume 15, Issue 3, 2019. DOI: [10.2174/1573400515666190617154129](https://doi.org/10.2174/1573400515666190617154129).
 17. **Krisar-White, P; Shad, MU**. Lithium and Lisinopril Interaction, Lithium Toxicities, and Relative Preservation of Renal Function in a Patient with Bipolar Disorder. *Psychiatric Annals*. 2019; 49(10):466-468. <https://doi.org/10.3928/00485713-20190909-01>.
 18. **Fryefield K, Shad MU**. Can low-dose aripiprazole reverse some of the adverse effects from a long-acting injectable? *Schizophr Res*. 2019 Feb; 204:417-418. doi: 10.1016/j.schres.2018.08.004. PMID 30121190.
 19. **Stearns TP, Shad MU, Guzman GC**. Glabellar Botulinum Toxin Injections in Major Depressive Disorder: A Critical Review. *Prim Care Companion C.N.S. Disord*. 2018 October 4; 20(5). PMID: 30326186. DOI: [10.4088/PCC.18r02298](https://doi.org/10.4088/PCC.18r02298)
 20. **Jones R, Shad M**. Aripiprazole-induced kleptomania: Case report. *J Affect Disord*. *Journal of Affective Disorders*, 244, 242-243. PMID 29884322
 21. **Luck, M, Turner M, Shad MU**. Effectiveness of genetically guided treatment in first-episode schizophrenia. *Schizophrenia Research*, 2018; 193: 441 – 442.
 22. **Chen Q, Calcagno HE, Shad M**. Efficacy of dextromethorphan/quinidine for patients with psychosis-related aggression: a retrospective case series. *Prim Care Companion CNS Disord*. 2018;20(3):18m02284.
 23. **Chiu SS, Woodbury-Farina M, Terpstra K, Badmaev V, Cernovsky Z, Bureau Y, Jirui, J, Raheb H, Husni, M, Copen J, Shad M, Srivastava A, Sanchez V, Williams M, Khazaeipoo Z, Carriere A, Chehade C** (2017) Targeting Epigenetics Signaling

with Curcumin: A Transformative Drug Lead in Treatment of Schizophrenia? *J Clin Epigenet.* Vol. 3 No. 3:32.

24. **Shad Mujeeb U** (2017) Worsening of anxiety symptoms with antipsychotic treatment in a patient misdiagnosed with schizoaffective disorder. *J. Depress Anxiety* S12: 001.
25. **Shad MU**. What do we know about insight into illness and its association with the underlying biology of schizophrenia? *Schizophr Res.* 193:41-42. 2018.
26. Chen Q, Ermann A, **Shad MU**. Effectiveness of dextromethorphan/quinidine in frontotemporal dementia. *Am J Geriatr Psychiatry.* 2018 Apr; 26(4):506
27. Chiu S, Woodbury M, Terpstra; Badmaev V, K, Cernovsky Z, Bureau Y, Hou JJ, Husni M, Copen J, **Shad MU**, Srivastava A, Sanchez V, Williams M, Khazaeipool Z, Carriere A, Chehade C. J Targeting epigenetics signaling with Curcumin: a transformative drug lead in the treatment of schizophrenia? *Journal of Clinical Epigenetics*; 2017; 3(3):32.
28. Perry-Rose J, Lenz K; **Shad, MU**. Delayed galactorrhea after discontinuation of risperidone in a schizophrenia patient. *Asian J Psychiatr.* 2017 14; 30:75-76.
29. Chiu S, Khan AS, Badmaev V, Terpstra K, Cernovsky Z, Varghese J, Khazaeipool Z, Elias H, Carriere A, Husni M, Copen J, **Shad MU**, Farina- Woodbury M, Johnson A, Chehade C, Suntres Z. Exploratory study of sublimed sulfur, in cognitively normal subjects and Alzheimer's dementia (AD) subjects: implications for sulfur targeting Hydrogen sulfide (H₂S)/ Homocysteine (Hcy) and beta-galactosidase (GALAC)/ Autophagy Signaling in AD *J Syst Integr Neurosci*, 2017 doi: 10.15761/JSIN.1000158.
30. **Shad MU**, Boothby A. Hyperprolactinemia with a low dose of risperidone in a young female. *Asian Journal of Psychiatry*, 2017, (27): 69–70.
31. Chiu S, Raheb H, Terpstra K, Vaughan J, Carrie A, Woodbury-Farina, M, Bureau Y, Badmaev V, Cernovsky Z, Bureau Y, Cernovsky Z, Hou J, Copen J, Husni M, Badmeav V, **Shad MU**, Suntras G, Gericke N. Exploring Standardized Zembrin® Extracts from the South African plant *Sceletium tortuosum* in Dual Targeting

- Phosphodiesterase-4 (PDE-4) and Serotonin Reuptake Inhibition as a potential treatment in schizophrenia. *Int J Comp Alter Med* 6 (5) 2017.
- 32.** Chiu S, Raheb H, Terpstra K, Vaughan J, Farina-Woodbury M, Cernovsky Z, Hou J, Copen J, Husni M, Badmeav V, Hategan A, **Shad, MU**, Suntras Z, Gericke N. Exploring Zembrin Extract Derived from South African Plant, *Sceletium tortuosum* in Targeting cAMP-driven Phosphodiesterase (PDE) Signaling in Alzheimer's Disease: Synthesis of Evidence. *Int J Ment Health Psychiatry* 1:2 2015
- 33.** **Shad, MU.**, Keshavan, SM. Neurobiology of Insight Deficits in Schizophrenia. *Schizophrenia Research* 2015 Jul; 165 (2-3):220-6.
- 34.** Chiu S, Woodbury-Farina, M, **Shad, MU**, Bureau Y, Cernovsky Z, Jurui JH, Husni M, Copen J, Raheb H, Terpstra K, Sacher V, Hategan A, Kaushal M. The role of nutrient-based epigenetic changes in buffering against stress, aging and Alzheimer's dementia. *Psychiatr Clin N Am* 37 (2014) 589–621.
- 35.** **Shad MU**, Prasad K, Forman SD, Haas GL, Walker JD, Pisarov LA, Goldstein G. Insight and Neurocognitive Functioning in Bipolar Subjects. *Comp Psychiatry* 2015 Jan; 56:112-20. doi: 10.1016/j.comppsy.2014.04.016. Epub 2014 May 2
- 36.** Brown, ES, Jeon-Slaughter H, Lu H, Jamadar R, Thomas S, **Shad M**, Denniston D, Tamminga CA, Uh J, Nakamura A, Thomas BP. Hippocampal Volume in Healthy Controls Given 3-Day Stress Doses of Hydrocortisone. *Neuropsychopharmacology* (20 Nov., 2014) | doi:10.1038/npp.2014.307
- 37.** Shad MU, Prasad K, Forman SD, Haas GL, Walker JD, Pisarov LA, Goldstein G. Insight and Neurocognitive Functioning in Bipolar Subjects. Accepted for publication by the *Comprehensive Psychiatry* 2014.
- 38.** Hashmi A, **Shad M**, Rhoades H, Grover M, Parsaik AK. Involuntary Detention: Comparison of Clinical Practices of Psychiatry Residents and Faculty. *Acad Psychiatry*. 2014 April 5.
- 39.** Hashmi A, **Shad M**, Rhoades HM, Parsaik AK. Involuntary Detention: Do Psychiatrists Clinically Justify Continuing Involuntary Hospitalization? Hashmi A,

Shad M, Rhoades HM, Parsaik AK. *Psychiatr Q.* 2014 February 26. [Epub ahead of print] PubMed PMID: 24570222.

40. Hasan KM, Ali H, **Shad MU**. Atlas-based and DTI-guided Quantification of Human Brain Cerebral Blood Flow: Feasibility, Quality Assurance, Spatial Heterogeneity, and Age Effects. *Magnetic Resonance Imaging* 31 (2013) 1445–1452.
41. *Didehbani, N., ***Shad MU** (*equally contributing authors), Tamminga, C. A., Kandalajt, M. R., Allen, T. T., Chapman, S. B., Krawczyk D. C. (2012). Insight and empathy in schizophrenia. *Schizophrenia Research*, 142, 246-247.
42. *Didehbani, N., ***Shad MU** (*equally contributing authors), Kandalajt, M. R., Allen, T., Tamminga, C. A., Krawczyk D. C., Chapman, S. (2012). Insight into illness and social attributional style in Asperger's syndrome. *Journal of Autism and Developmental Disorders*, 42, 2754-2760.
43. **Shad MU**, Keshavan M, Steinberg JL, Mihalakos P, Thomas B, Motes, M, Soares JC, Tamminga CA (2012). Neurobiology of Self-Awareness in Schizophrenia. *Schizophr Res.* 138 (2012) 113–119
44. **Shad M**, Muddasani S, Rao U (2011). Grey matter deficits in depressed adolescents: A voxel-based morphometry study. *J Child and Adolesc Psychopharm.* 2012 Jun; 22(3): 190–197.
45. **Shad MU**, Brent BK, Keshavan M (2012). Neurobiology of Self-Awareness in Schizophrenia: A hypothetical Model. *Asian J Psychiatry* 4(4): 248-254.
46. **Shad MU**, Bidesi AP, Chen LA, Ernst M, Rao U. Neurobiology of decision making in depressed adolescents: a functional magnetic resonance imaging study. *J Am Acad Child Adolesc Psychiatry.* 2011 Jun; 50 (6):612-621.e2.
47. **Shad MU**, Suris A, North C (2011). Novel Combination Strategy to Optimize Treatment for PTSD. *Human Psychopharmacology: Clinical and Experimental.* 2011 February 9.
48. **Shad MU**, Bidesi AS, Chen L, Binu Thomas, Ernst M, Rao U (2011). Neurobiology of Decision-Making in Adolescents. *Behavioural Brain Research* Volume 217, Issue 1, February 2, 2011, Pages 67-76.

49. Rao U, Chen L, Bidesi AS, **Shad M**, Thomas A, Hammen CL (2010). Hippocampal Changes Associated with Early-Life Adversity and Vulnerability to Depression. *Biological Psychiatry* 67: 357-364.
50. Husain S, Kuzminski S, **Shad MU**, Gabrielson B, Bret ME, Osuji IJ, Brown ES: Cognition and dorsolateral prefrontal cortex volume in corticosteroid-treated patients given lamotrigine. *Stress and Health* 27:18-24 (2010).
51. Desai S, Khanani S, **Shad MU**, Brown ES (2009). Attenuation of Amygdala Atrophy with Lamotrigine in Patients Receiving Corticosteroid Therapy. *J Clin Psychopharmacol* 29:284-287.
52. **Shad MU** (2008). Clozapine Toxicity: A Discussion of Pharmacokinetic factors. *Asian J Psych* 47-49.
53. Sellin A, **Shad MU**, Tamminga CA (2008). Muscarinic Agonists for the Treatment of Cognition in Schizophrenia. *CNS. Spectr* 13:11.
54. Brown S, Wolfshohl J, **Shad MU**, Vazquez M, Osuji J. Attenuation of the Effects of Corticosteroids on Declarative Memory with Lamotrigine. *Neuropsychopharmacology* (2008) 33, 2376–2383.
55. **Shad MU**, Keshavan MS, Tamminga CA, Cullum M, David AS. Neurobiological underpinnings of insight deficits in schizophrenia. *Int Rev Psychiatry*. 2007 Aug;19 (4):437-46. Review.
56. **Shad MU**, Tamminga CA, Cullum CM, Haas GL, Keshavan MS (2006). Insight and Frontal Cortical Function: A Review. *Schizophrenia Research* 86, 54-70.
57. **Shad MU**, Mudassani S, Keshavan MS. Insight and Prefrontal Sub-Regions in First-Episode Schizophrenia – A Pilot Study (2006). *Psychiatry Research: Neuroimaging*, 146, 35-42.
58. Kilbourne, AM; Bauer, MS; Han, X; Haas, G; Elder, P; Good, CB; **Shad, M**; Conigliaro, J; Pincus, HA (2005). Racial Differences in the Treatment of Veterans with Bipolar Disorder. *Psychiatric Services* 56:1549-1555.

59. Kilbourne AM, Cornelius JR, Han X, Pincus HA, **Shad M**, Salloum I, Conigliaro J, Haas GL. Burden of general medical conditions among individuals with bipolar disorder. *Bipolar Disord* 2004; 6: 368-373.
60. **Shad MU**, Mudassani S, Prasad K, Diwadkar V, Sweeney j, Keshavan MS. Insight and DLPFC Function in First-Episode Schizophrenia. *Neuroimage* 2004; 22(3): 1315-1320.
61. **Shad MU**, Mudassani S, Prasad K, Diwadkar V, Sweeney j, Keshavan MS. Insight and DLPFC Function in First-Episode Schizophrenia. *Neuroimage* 2004; 22(3): 1315-1320.
62. Keshavan MS, **Shad MU**, Schooler N. Efficacy and Tolerability of Olanzapine Treatment in Schizotypal Personality Disorder. *Schizophr Res* 71 (2004) 97-101.
63. **Shad MU**. A Complex Interaction between Clozapine and Phenytoin. *J Pharm Technol* 2004; 20: 280-2.
64. **Shad MU**, Marsh C, Preskorn SH. The Economic Consequences of a Drug-Drug Interaction. *J. Psychopharmacol.* 2001 Feb;21(1):119-20.
65. **Shad MU**, Preskorn SH, Izzur Z. Failure to Consider Drug-Drug Interactions as a Likely Cause of Behavioral Deterioration in a Patient with Bipolar Disorder. *J Clin Psychopharmacol* 2000;20(3):390-1.
66. Khan A, **Shad MU**, Preskorn SH. Lack of Sertraline Efficacy Probably Due to an Interaction with Carbamazepine. *J Clin Psychiatry* 2000; 61(7):526-7.
67. **Shad MU**, Preskorn SH. A drug-Drug Interaction in Reverse: Loss of Phenytoin Efficacy as a Result of Fluoxetine Discontinuation: a case report. *J Clin Psychopharmacol*, 1999 Oct;19(5): 471-2.
68. **Shad MU**, Preskorn SH. "Pharmacodynamic and pharmacokinetic factors in a case of Neuroleptic Malignant Syndrome. *J Clin Psychopharmacol* 1998 Aug; 18(4):346-7
69. **Shad, MU**, Harvey AT, Lucot JB. A possible pharmacokinetic interaction between fluoxetine and acetylsalicylic acid. *J Clin Psychiatry*, 1997 Dec;58(12) 549-550.

- 70. Shad MU**, Preskorn SH. Pharmacotherapy for the Major Depressive Disorder: Selection of an Antidepressant. *The Medical Spectrum* (Journal of Pakistan Medical Association, Karachi, Pakistan), 1997; 18: 22-26.
- 71. Shad MU**, Preskorn SH. A possible bupropion and imipramine interaction [letter]. *J of Clin Psychopharmacology*, 1997 Apr; 17(2):118-9.

CME REVIEWS

- 72. Shad MU**. *Biopsychosocial Aspects of COVID-19 in the Geriatric Population Part I: Directions in Psychiatry*. 2021; 4 1(3): 165-180.
- 73. Shad MU**. *A Review of Psychopharmacotherapy of Geriatric Depression Part I: Directions in Psychiatry*. 2020; 40(4):277-285.
- 74. Shad MU**. *A Review of Psychopharmacotherapy of Geriatric Depression Part II: Directions in Psychiatry*. 2020; 40(4):287-301.
- 75. Shad MU**. Aga, VM. *Clinical relevance of drug interactions in the Geriatric population: A Review*. *Directions in Psychiatry*. 2020; 40(2):115-125.
- 76. Shad MU**. *Genetic Basis of Efficacy & Tolerability with Antipsychotic Drugs: A Review*. *Directions in Psychiatry*. 2019; 39(1): 29-46.
- 77. Shad MU**. *Insight deficits in schizophrenia*. *Directions in Psychiatry*. 2017; 37(4):1-5.

BOOK CHAPTERS:

- 78.** Simon S. Chiu, Kristen Terpstra, Michel Woodbury-Farina, Vladimir Badmaev, Josh Varghese, Hana Raheb, Ed Lui, Zack Cernovsky, Yves Bureau, Mariwan Husni, John Copen, **Mujeeb Shad**, Autumn Carriere, Zahra Khazaeipool, Weam Sieffien, Marina Henein, Brendan Casola, Siddhansh Shrivastava In: *Nutraceuticals in Brain Health and Beyond* (2021). 1st Edition, Chapter 18, "Transforming curry extract-spice to liposome-based curcumin: lipocurc to restore and boost brain health in COVID-19 syndrome."

79. Vimal Aga, MD, **Mujeeb Shad, MD, MSCS**, Hongru Zhu, M.D., Ph.D.; Carl Salzman, MD In: Nathan Hantke, Amit Etkin, Ruth O'Hara eds. (2020): Handbook of Mental Health and Aging." 3rd Edition. Psychopharmacologic Treatment." Section V: "Assessment, Treatment, and Prevention."
80. **Mujeeb U Shad, M.D., M.S.C.S.** In: Massoud Stephane, Flavie Waters, Ph.D. eds. (2015): The Assessment of Psychosis: A Compendium of Assessment Scales for Psychosis". First Edition. "Language disorder" Section III: "The assessment of psychotic symptoms."
81. **Mujeeb U Shad, M.D., M.S.C.S.** In: Matcheri S. Keshavan, ed. Future Science Group, Antipsychotics for Schizophrenia (electronic book), 1st Edition (2011): Unmet Medical Needs in Schizophrenia (Chapter 3).
82. Carol A. Tamminga, M.D., **Mujeeb U. Shad, M.D.**, Subroto Ghose, M.D., Ph.D. In: Stuart C. Yudofsky, ed. APA Psychiatric Publishing Textbook of Neuropsychiatry and Neurosciences, 5th Edition: Neuropsychiatric Aspects of Schizophrenia.
83. **Mujeeb U. Shad, M.D.**, Carol A. Tamminga, MD. In: Gunvant K. Thaker, ed. Year in Schizophrenia: Drug Discovery 15: 291-310. Clinical Publishing Press, Oxford, UK.
84. **Mujeeb U. Shad, M.D.**, Sheldon H. Preskorn, M.D. In: Rene H. Levy, ed. Metabolic Drug Interactions: Drugs as inhibitors of metabolic enzymes: Antidepressants 42: 563-577, Lippincott Williams and Wilkins, Philadelphia, PA.
85. **Mujeeb U. Shad, M.D.**, Sheldon H. Preskorn, M.D. Marco Antonio Marcolin, Ph.D. Interacoes Farmocologicas Com Drogas Antidepressivas. In: Marco Antonio Marcolin ed. Interacoes Farmacologicas Com Drogas Psiquiatricas, Capitulo 2: 21-91, MEDSI, Rio de Janeiro, Brazil 1998.

CURRICULUM DEVELOPMENT

1. **Mujeeb U. Shad.** Chair, subcommittee for innovative teaching strategies in psychopharmacology: Problem-Based Learning in Psychopharmacology for the American Society of Clinical Psychopharmacology (ASCP), 5034A Thoroughbred Lane, Brentwood, TN 37027.

- 2.** Charles O'Brien, CP; **Mujeeb U Shad.** Psychopharmacology of Addiction and Neurobiology of Addiction Part I and II. ASCP Model Psychopharmacology Curriculum for Residents/Mental Health Clinicians, 10th Edition, 2019, American Society of Clinical Psychopharmacology, 5034A Thoroughbred Lane, Brentwood, TN 37027.
- 3.** Donald W. Black, Larry J. Siever, MD; **Mujeeb U. Shad.** Psychopharmacology of Personality Disorders. ASCP Model Psychopharmacology Curriculum for Mental Health Clinicians and residents, 10th Edition, 2019, American Society of Clinical Psychopharmacology, 5034A Thoroughbred Lane, Brentwood, TN 37027.
- 4.** **Shad, M.** Basic Psychopharmacology. ASCP Model Psychopharmacology Curriculum for Medical Students, Primary Care Residents/Mental Health Clinicians, 5th Edition, 2019, American Society of Clinical Psychopharmacology, 5034A Thoroughbred Lane, Brentwood, TN 37027.
- 5.** O'Brien, CP; **Shad, M.** Psychopharmacology of Addiction and Neurobiology of Addiction Part I and II for Medical Students, Primary Care Residents/Mental Health Clinicians, 4th Edition, 2018, American Society of Clinical Psychopharmacology, 5034A Thoroughbred Lane, Brentwood, TN 37027.

ABSTRACTS:

1. Shahzain, Mujeeb Shad. Dispensing Practices for Psychotropic Medications in Karachi, Pakistan. Presented at the Virtual Inaugural Psychiatric Summit, 2022.
2. Ahmad Soltani, Elham Soltani, Maryam Pishva, Seyedamirhossein Pishva, **Mujeeb U. Shad.** Effect of Intrathecal Baclofen Pump on spasticity and level of consciousness in patients with Traumatic Brain Injury. Accepted by the 22nd World Psych Association World Congress of Psychiatry Bangkok 3-6 August 2022

Curriculum Vitae

Mujeeb U. Shad, M.D., M.S.C.S

3. E. Soltani, H. Bateni, **M. Shad**. Mechanism of Action of Ketamine to Address Major Depressive Disorder. Accepted by the 22nd World Psych Association World Congress of Psychiatry Bangkok 3-6 August 2022.
4. Youshay Jawad, Fauzia Arain, Umer Suleman, **Mujeeb Shad**. Effectiveness of High-Dose Maintenance Therapy in Treatment-Refractory Schizophrenia. Present at the annual APA meeting 23rd May 2022 in New Orleans.
5. Shahzain Hasan, **Mujeeb U Shad**. Dispensing Practices for Psychotropic Medications Amongst Pharmacists in Karachi, Pakistan. Present at the first virtual conference of Psychiatry Summit 2022.
6. Sana Javed, **Mujeeb Shad**. Covid-19 associated Psychosis in adolescents- A Case Based Review. Approved to be presented at the 30th European Congress of Psychiatry, 2-5th April, 2022 in Budapest, Hungary.
7. Soltani, E., Ahmad, N., Suleman, U., & **Shad, M.** (2021). *Different modalities on transcranial magnetic stimulation to manage schizophrenia*. Paper presented at the 21st WPA World Congress of Psychiatry, Virtual.
8. S. Chiu, A. Carriere, C. John, M. Husni, M. **Shad, M.** Woodbury-Farina, Z. Cernovsky. Exploring schizophrenia (Dementia Praecox), Alzheimer's dementia (AD), and COVID-19: Converging on cardiovascular metabolic (CVM) risks: post-Hoc analysis of Ginsana-115 study in treatment resistant schizophrenia. Abstract submitted at the International Conference on Alzheimer's and Parkinson's Disorders and Related Neurological Disorders Barcelona, Spain March 15-20, 2022.
9. Soltani, E., Ahmad, N., Suleman, U., **Shad, M.** (2021). *Pros and cons of using transcranial magnetic stimulation to address schizophrenic patients*. Paper presented at the 4th International Brain Stimulation Conference, Charleston, South Carolina.
10. E. Soltani, H. Bateni, K. Ali, M. Shad. *Changes of postural steadiness following TMS treatment in individuals with major depressive disorder*. Presented at the

21st WPA World Congress of Psychiatry, Virtual Congress between 18-21 October 2021.

11. Bukhari, A., Hameed, T.A., Usmani, S., Chaudary, A.F., Javed, S., Tunio, K., Mansoor, I., Saad, M., Arain, F., **Shad, M.**, Neurocognitive outcomes in anti-NMDAR encephalitis. Presented at the WPA World Congress of Psychiatry 21st Annual Meeting virtual congress 18-21 October 2021, Cartagena, Colombia.
12. Sajnani, P.K., Qureshi, G.F., Bazaz, S.A., Choudhry, A.S., Arain, F., **Shad, M.**, Cannabis and Schizophrenia: Untangling the linkage. Presented at the WPA World Congress of Psychiatry 21st Annual Meeting virtual congress 18-21 October 2021, Cartagena, Colombia.
13. Mansoor, I., Hameed, A.T., Bukhari, A., Chaudhry, F., Usmani, S., Javed, S., Tunio, K., Saad, M., Arain, F., **Shad, M.**, Etiobiology of anti-NMDAR Encephalitis. Presented at the WPA World Congress of Psychiatry 21st Annual Meeting virtual congress 18-21 October 2021.
14. Tunio, A.K., Usmani, S., Mansoor, I., Saad, M., Javed, S., Hameed, T.A., Bukhari, A., Chaudhry, A.F., Arain, F., **Shad, M.**, Anti-N-Methyl-D-Aspartate-Receptor Encephalitis and autonomic instability: A review. Presented at the at the WPA World Congress of Psychiatry 21st Annual Meeting virtual congress 18-21 October 2021, Cartagena, Colombia.
15. Bazaz, A., Choudhry, S., Sajnani, P.K., Qureshi, F., Arain, F., **Shad, M.**, Does autoimmunity plays a role in schizophrenia and its management. Presented at the WPA World Congress of Psychiatry 21st Annual Meeting virtual congress 18-21 October 2021, Cartagena, Colombia.
16. Qureshi, F., Sajnani, P.K., Choudhry, S., Bazaz, A., Arain, F., **Shad, M.**, Multimodal resilience factors in schizophrenia. Presented at the WPA World Congress of Psychiatry 21st Annual Meeting virtual congress 18-21 October 2021, Cartagena, Colombia.
17. Tanweer, A., Chaudhary, F., Bukhari, A., Usmani, S., Mansoor, I., Tunio, K., Javed, S., Saad, M., Arain, F., **Shad, M.**, Neuropsychiatric symptoms of anti-

Curriculum Vitae

Mujeeb U. Shad, M.D., M.S.C.S

NMDA receptor encephalitis. Presented at the WPA World Congress of Psychiatry 21st Annual Meeting virtual congress 18-21 October 2021, Cartagena, Colombia.

18. Choudhry, S., Bazaz, A., Qureshi, F., Sanjana, P.K., Arain, F., **Shad, M.**, Is infections one of the predisposing factors in schizophrenia. Presented at the WPA World Congress of Psychiatry 21st Annual Meeting virtual congress 18-21 October 2021, Cartagena, Colombia.
19. Hameed, T.A., Bukhari, A., Chaudhry, F., Tunio, K., Mansoor, I., Usmani, S., Saad, M., Javed, S., Arain, F., **Shad, M.** "Light Switch" Mental status changes and sleep disturbances in anti-NMDA receptor encephalitis. Presented at the WPA World Congress of Psychiatry 21st Annual Meeting virtual congress 18-21 October 2021, Cartagena, Colombia.
20. Usmani, S., Javed, S, Tai, S., Tunio, K., Tanweer, A., Chaudhary, F., Bukhari, A., Mansoor, I., Arain, F., **Shad, M.**, Neuropsychiatric symptoms of anti-NMDA receptor encephalitis in children vs. adults. Presented at the WPA World Congress of Psychiatry 21st Annual Meeting virtual congress 18-21 October 2021, Cartagena, Colombia.
21. **Mujeeb U. Shad.** Innovative Psychopharmacology in Treatment-Refractory Patient
22. Population. Presented at the virtual annual meeting of American Psychiatric Meeting, May 2021.
23. **Mujeeb U. Shad.** An Interactive Discussion of Innovative Psychopharmacology in Treatment-Refractory Patient Population in Psychiatry. Presented at the virtual annual meeting of the American Society of Clinical Psychopharmacology, May 2020 (virtual meeting due to COVID19).
24. Abigail Wagner, M.D., **Mujeeb Shad, MD, MSCS.** Relationship between clozapine levels and acute inflammatory stress. Presented at the virtual APA annual meeting April 2020 in Philadelphia, PA (virtual meeting due to COVID19).

Curriculum Vitae

Mujeeb U. Shad, M.D., M.S.C.S

25. Susan, S., **Shad, MU.** "Can aripiprazole be used to manage antipsychotic-induced hyperprolactinemia? A retrospective case series. Presented at the annual APA meeting April 2020 in Philadelphia, PA (virtual meeting due to COVID19).
26. **Shad, MU.** Is there any association between anxiety symptoms and valsartan treatment? Poster presented virtually at the annual APPA April 2020 meeting in Philadelphia, PA (virtual meeting due to COVID19).
27. Zahra Khazaei; Simon Chiu; Hana Rabeb, Kristen Tempstra, Zack Cernovksy; Robbie Campbell, Mariwan Husni; John Copen; Michel Woodbury-Farina, **Mujeeb Shad.** Pilot study of cardio-vascular-metabolic risk factors intercepting with neuro-cognition in atypical parkinsonian syndrome (APS) and tardive dyskinesia in schizophrenia. Poster presented at the XXIV World Congress on Parkinson's disease and Related Disorders June 2019, Montreal, Canada.
28. Zahra Khazaei; Simon Chiu; Zack Cernovksy; Gurpreet Sidhu; Mariwan Husni; John Copen; Michel Woodbury; **Mujeeb Shad**; Autumn Carriere. Exploring the emerging role of testosterone-coupled-opiate receptor signaling in gambling, alcohol, and smoking craving in opiate use disorder. Poster presented at the annual meeting of the American Psychiatric Association in San Francisco in May 2019.
29. Patricia Krisar-White, **Mujeeb U Shad.** Interaction between lithium and lisinopril and renal resilience in a patient with bipolar disorder. Poster presented at the annual meeting of the American Psychiatric Association in San Francisco in May 2019.
30. Torren P. Stearns, **Mujeeb U. Shad**, Gabriela C Guzman, AA Alternative Treatments for Major Depression: Glabellar Botulinum Toxin Injections. Presented at the annual meeting of the American Psychiatric Association in San Francisco in May 2019.
31. **Mujeeb U. Shad**, MD, MSCS. "An Interactive Discussion of Innovative Psychopharmacology in Treatment-Refractory Patient" presented at the

Curriculum Vitae

Mujeeb U. Shad, M.D., M.S.C.S

American Psychiatric Association's annual meeting in San Francisco in May 2019.

32. **Mujeeb U. Shad, MD, MSCS.** "An Interactive Discussion of Innovative Psychopharmacology in Treatment-Refractory Patient," presented at the American Society of Clinical Psychopharmacology annual meeting in Scottsdale, Arizona, May 2019.
33. Chiu S, Copen J, Husni M, Campbell R, Woodbury-Farina M, **Shad MU.** Multisite RCT of Panax Ginseng Targeting NMDA and Epigenetics Signaling in Negative and Depressive Symptoms in Treatment-Resistant Schizophrenia. A poster at the annual APA meeting in New York 2018.
34. **Mujeeb U. Shad, MD. M.S.C.S.,** Matcheri S. Keshavan, M.D. Neurobiology of Insight Deficits in Schizophrenia: An fMRI Study. Poster presented at the annual meeting SOBP meeting in Toronto, CA 2015.
35. E. Sherwood Brown, Haekyung Jeon-Slaughter, Hanzhang Lu, Rhoda Jamadar, Sruthy Thomas, **Mujeeb Shad,** Daren Denniston, Carol Tamminga, Jinsoo Uh, Binu P. Thomas. Rapid Changes in Hippocampal Volume with Hydrocortisone Administration. Presented at the annual meeting of ACNP 2014.
36. **Mujeeb U. Shad, MD. M.S.C.S.,** Matcheri S. Keshavan, M.D. Perry Mihalakos, M.S., Binu P. Thomas, M.S., Michael A. Motes, Ph.D. Jair C. Soares, M.D., Carol A. Tamminga, MD. Neurobiology of Insight Deficits in Schizophrenia. Poster presented at the annual meeting SOBP meeting in Philadelphia, PA 2012.
37. **Mujeeb U. Shad, MD. M.S.C.S.,** Matcheri S. Keshavan, M.D. Perry Mihalakos, M.S., Binu P. Thomas, M.S., Michael A. Motes, Ph.D. Jair C. Soares, MD. Carol A. Tamminga, MD. Metacognitive Assessment of Self-Awareness in Schizophrenia. Poster presented at the annual meeting ACNP meeting in Hawaii 2011.
38. Singh G, MS, MS1*; Brown D, BS, MS1*; Denniston D, BS; Gabrielson B, BS; **Shad MU, MD,** MSCS; Brown ES, MD. Phenytoin protects against Corticosteroid-induced memory loss in healthy controls. Poster presented at the

Curriculum Vitae

Mujeeb U. Shad, M.D., M.S.C.S

48th Annual UT Southwestern Medical Student Research Forum on January 19, 2010.

39. **Shad MU**, Thomas B, Mihalakos P, Faryal M, Rastegari M, Tamminga CA. Impact of Pharmacotherapy on Hippocampal Volume and Function in Schizophrenia. Poster presented at the biannual meeting of the International Congress on Schizophrenia Research, San Diego, CA, on May 31, 2009.
40. **Shad MU**, Muddasani S, Thomas B, Tamminga CA. Structural Correlates of Insight in Schizophrenia. Poster presented at the annual meeting of the Society of Biological Psychiatry, San Diego, CA, on May 19, 2007.
41. Muddasani S, **Shad MU**, Thomas B, Tamminga CA. Insight and Cerebellum in Schizophrenia. Poster presented at the annual meeting of the Society of Biological Psychiatry, San Diego, CA, on May 19, 2007.
42. **Shad MU**, Muddasani S, Thomas B, Moore D, Tamminga CA. Insight and Parietal Cortex in Schizophrenia. Poster accepted for presentation at the International Congress on Schizophrenia Research in Colorado Springs, CO, in April 2007.
43. Brown ES, Zaidel L, Wolfshohl J, Allen G, Shad MU, McColl R, Vazquez M, Osuji J, Ringel WK: Attenuation of the Effects of Corticosteroids on the Human Hippocampus with a Glutamate Release Inhibitor. American College of Neuropsychopharmacology, ACPN 45th Annual Meeting, NR 42, Hollywood, Florida, December 3-7, 2006.
44. Hubbard MJ, Tamminga CA, Wolfshohl J, Alay Parikh, **Shad MU**, Brown SE. Lamotrigine Treatment for Corticosteroid-Induced Hippocampal Changes. Poster presented at the Annual Biomedical Research Conference for Minority Students (ABRCMS) at Anaheim, CA, on November 10, 2006.
45. Goldstein G, Jacoby A, Cornelius L, **Shad, MU**, Haas GL. Cognitive Function and Insight in Bipolar Disorder. Archives of Clinical Neuropsychology, 21, A34, 2006.
46. **Shad MU**, Thomas B, Chin R, Eamma J, Tamminga CA. Neurobiological Correlates of Insight in Schizophrenia. Poster presented at the annual meeting of Society of Biological Psychiatry Meeting, Toronto Canada, May 2006.

Curriculum Vitae

Mujeeb U. Shad, M.D., M.S.C.S

47. Goldstein G, Jacoby A, Cornelius L, Haas GL, **Shad, MU**. Insight & Cognitive Function in Alcoholism Comorbid with Bipolar Disorder. Poster presented on June 23, 2006, at RSA meeting in Baltimore, MD.
48. Mark Benton, **Mujeeb U. Shad**, Vaibhav Diwadkar, Rajaprabhakaran Rajarethinam, Richard C, Jeffrey Stanley, Matcheri Keshavan. Neuronal Circuitry Underlying Insight in Schizophrenia. Poster presented at the Human Brain Mapping conference in Toronto, Canada June 2005.
49. Kevin Murch, M Shepard, James Eamma, Binu Thomas, Sangeeta Awasthi, **Mujeeb Shad**, Laurie Rillings, M Cullum, J Osudi, A Belleck, Carol Tamminga. Does Cognitive Remediation Contribute to Cognitive Enhancement in Schizophrenia? Abstract presented at the International Congress of Schizophrenia Research meeting in Savannah, GA, on 4thth April 2005.
50. **Mujeeb U. Shad, M.D.**, Jeff Stanley, Ph.D. Matcheri S. Keshavan, MD ¹H-MRS Study of Insight Deficits in First-Episode Schizophrenia. Abstract presented at the annual Research Day of Western Psychiatric Institute and Clinic, the University of Pittsburgh, in June 2004.
51. **Mujeeb U. Shad, M.D.**, Sri Muddasani, M.D., Kevin D. Eklund, B.S. A.R.N.P., Matcheri S. Keshavan, M.D. Prefrontal Sub-Regions and Dimensions of Insight in First-Episode Schizophrenia. Abstract presented at the annual meeting of the Society of Biological Psychiatry in New York on April 29, 2004.
52. **Mujeeb U. Shad, M.D.**, Nina Schooler, PhD., Matcheri Keshavan, MD. *Efficacy and Tolerability of Olanzapine in the Treatment of Schizotypal Personality Disorder*. Abstract presented at the annual meeting of Biological Psychiatry May 2003 at San Francisco, CA.
53. Huma Aziz, M.D., **Mujeeb Shad, M.D.**, Jaspreet Brar, M.D. *Effect of Smoking on Clozapine Levels*. Abstract presented at the annual meeting of the American Psychiatric Association May 2003 at San Francisco, CA.

Curriculum Vitae

Mujeeb U. Shad, M.D., M.S.C.S

54. **Mujeeb Shad, M.D.**, Huma Aziz, M.D., Jaspreet Brar, M.D. *Effect of Smoking on Clozapine Levels*. Abstract presented at the Western Psychiatric Institute and Clinic's Research Day in June 2003.
55. Sri Muddasani, M.D., **Mujeeb U. Shad, M.D.**, Prasad Konasale, MD, Vaibhav Diwadkar, Ph.D., Matcheri Keshavan, MD. *Planum Temporale and Heschl's Gyrus Volumes in First-Episode Schizophrenia and Their Relationship with Psychopathology*. Abstract presented at the Western Psychiatric Institute and Clinic's annual Research Day in June 2003.
56. Kilbourne A, Cornelius JR, **Shad MU**, Salloum I, Conigliaro J, Haas GL. Burden of Medical Comorbidities among Individuals with Bipolar Disorder. Abstract presented at the annual meeting of the American Association for Geriatric Psychiatry 2003.
57. Sarah D. Sahni, **Mujeeb U. Shad, M.D.**, Ilona Mankowski, Anita Patel, M.D., Vaibhav Diwadkar, M.D., Matcheri Keshavan, M.D. Insight and the Prefrontal Cortex in Psychotic Disorders. Presented at the annual meeting of Biological Psychiatry on May 16, 2002, in Philadelphia, PA.
58. Sarah D. Sahni, **Mujeeb U. Shad, M.D.**, Ilona Mankowski, Anita Patel, M.D., Vaibhav Diwadkar, M.D., Matcheri Keshavan, M.D. Insight and the Prefrontal Cortex in Psychotic Disorders. Presented at the annual Western Psychiatric Institute and Clinic Research Day on June 18, 2002.
59. **Mujeeb U. Shad, M.D.**, Cheryl C. Carmichael, BS., Sheldon H. Preskorn, M.D., Dale W. Horst, Ph.D. Prevalence of Polypharmacy in Different Clinical Settings: Its Relation to Drug-Drug Interactions (An update). A poster presented at the American Psychiatric Association's annual meeting on May 15, 2000, in Chicago, IL.
60. **Mujeeb U. Shad, M.D.**, Sheldon H. Preskorn, M.D., Akhter Alam, M.D. Effect of Education on Resident Training. A poster presented at the 51st meeting of the Institute on Psychiatric Services, 1999 in New Orleans, LA.

Curriculum Vitae

Mujeeb U. Shad, M.D., M.S.C.S

61. **Mujeeb U. Shad, M.D.**, Cheryl Carmichael, B.S., Sheldon H. Preskorn, M.D., Dale W. Horst, Ph.D. Prevalence of polypharmacy in different clinical settings and its relation to drug-drug interactions (Update). Poster presented at the annual meeting of American Psychiatric Association, 1999 in Washington DC.
62. **Mujeeb U. Shad, M.D.**, Sheldon H. Preskorn, M.D., Akhter Alam, M.D., Cheryl A. Carmichael, BS. Effect of Education in Psychopharmacology in Prescribing Practices in a Resident Psychiatric Outpatient Clinic. A poster presented at the annual meeting of American College of Clinical Pharmacology, 1999 in Rockville MD
63. **Mujeeb U. Shad, M.D.**, Sheldon H. Preskorn, M.D., Jeff Miceli, M.D., Keith Wilner, Ph.D. Use of population pharmacokinetic modeling to characterize intramuscular pharmacokinetics for ziprasidone in schizophrenic patients. *Abstract Clin Pharm Therap.* 65::171, 1999
64. **Mujeeb U. Shad, M.D.**, Cheryl Carmichael, B.S., Sheldon H. Preskorn, M.D., Dale Horst, Ph.D. The nature and extent of polypharmacy in patients on antidepressants as a function of treatment setting. *Abstract Clin Pharm Therap.* 65:183, 1999.
65. **Mujeeb U. Shad, M.D.**, Sheldon Preskorn, M.D., Anne Harvey, Ph.D., Jeff Alderman, MD. Fluoxetine: Pharmacokinetics and CYP 2C19 Inhibition. Abstract presented at the 50th Institute on Psychiatric Services, 1998 in Los Angeles, CA.
66. **Mujeeb U. Shad, M.D.**, Sheldon Preskorn M.D., Anne Harvey, Ph.D. Inhibition of Platelet 5HT Uptake by Sertraline. Abstract presented at the 50th Institute on Psychiatric Services, 1998 in Los Angeles, CA.
67. S.H. Preskorn, M.D., **M. Shad, M.D.**, J. Alderman, Ph.D., R. Lane, M.D. Fluoxetine: Age and Dose-Dependent Pharmacokinetics and CYP 2C19 Inhibition. Abstract presented at the annual meeting of the *American Society for Clinical Pharmacology and Therapeutics in 1998.*
68. SH Preskorn, M.D., J. Alderman, Ph.D., D.J. Greenblatt, M.D., D. Horst, Ph.D., **M.U. Shad, M.D.** Sertraline Does not Inhibit Cytochrome P-450 (CYP) 3A-Mediated Drug Metabolism, *In Vivo*. Abstract presented at the 7th annual meeting of

Curriculum Vitae

Mujeeb U. Shad, M.D., M.S.C.S

Research Forum, sponsored by University of Kansas School of Medicine-Wichita and *Second International Conference of Drug-drug interactions*, November 1997, Baltimore, MD.

69. SH Preskorn, M.D., K. OMO, RD Magnus, M.D., **MU Shad, M.D.** Immediate Crossover from Fluoxetine to Mirtazapine. Presented at the 150th Annual Meeting of the *American Psychiatric Association*, May 17-22, 1997 San Diego, CA and 52nd Annual Convention of *Society for Biological Psychiatry*, May 14-18, 1997, San Diego, CA.
70. **M. U. Shad, M.D.**, Cheryl A. Carmichael, S.H. Preskorn, M.D., W.D. Horst, Ph.D. Prevalence of Polypharmacy in Patients on Antidepressants and its Relation with Drug-drug Interactions. Presented at the 150th Annual Meeting of *American Psychiatric Association*, May 17-22, 1997, San Diego, CA.
71. **Mujeeb U. Shad, M.D.**, Cheryl A. Carmichael, Sheldon H. Preskorn, MD, W. Dale Horst Ph.D. Prevalence of Polypharmacy in different Clinical Settings and its Relation to Drug-drug interactions. Presented at the Sixth Annual *Research Forum of Kansas Univ., School of Medicine-Wichita*, October 10, 1996, Wichita, KS.

WORKSHOPS/SEMINARS/GENERAL SESSION

Chair: Mujeeb U. Shad, MD, M.S.C.S. Presenter: Ahmad Rehan Khan, M.D. Presenter: Fauzia Arain, M.D. Presenter: Manal Khan, M.D., Kiran Khalid, M.D. A general session titled "Roadmap to Psychiatry Residency for International Medical Graduates." presented at the virtual annual meeting of the American Psychiatric Association, May 2021.

Chair: Mujeeb U. Shad, MD, M.S.C.S. Presenter: Ahmad Hameed, MD, Presenter: Du, Wei. Presenter: Obiora Onwuameze, MD. A general session, titled "Problem-Based Learning: An Innovative Approach to Teach Advances in Psychopharmacology of Mind and Brain." Presented at the virtual annual meeting of the American Psychiatric Association, May 2021.

Curriculum Vitae
Mujeeb U. Shad, M.D., M.S.C.S

Chair: Muhammad Zeshan, MD, Chair: Panagiota Korenis, MD, Presenter: Ahmad Hameed, MD, Presenter: Mujeeb U Shad, MD, MS Presenter: Michelle P. Durham, MD, MPH. A seminar titled "Finding Your Match: The Process of Obtaining Residency Positions" presented at the annual meeting of the American Psychiatric Association in San Francisco, CA, May 19, 2019.

Chair: Jose Rubio, Presenter Mujeeb U Shad. "A seminar titled, "ASCP Psychopharmacology Curriculum" presented at the annual meeting of the American Psychiatric Association in New York 2018.

Chair: Simon Chiu, Presenter Mujeeb U. Shad. A seminar titled, "Gut microbiota intersects with brain health at epigenetics cross-roads of Alzheimer's disease," in a seminar titled, "Exploring Epigenetics-Driven Multimodal Interventions: Diets, Nutraceuticals, Exercises, and Brain Games in Alzheimer Dementia," presented at the Annual Meeting of American Psychiatric Association in San Diego May 21, 2017.

Chair: Simon Chiu, Presenter Mujeeb Shad. A seminar titled, "Exploring diets, E-games, and exercises targeting epigenomics in boosting cognitive health in Alzheimer's dementia: Promises, evidence, and challenges," presented at the annual meeting of American Psychiatric Association 2014, New York NY.

CME PRESENTATIONS

“Neurobiological Effects of COVID-19 in the Geriatric Population” virtually presented at the meeting titled “COVID-19 and its Long-Term Impact on Mental Health Care and Learning, What Lessons Can Be learnt? by the for World Association for Psychosocial Rehabilitation – WAPR-UK with Pennine Care NHS Foundation Trust (PCFT), British Pakistani Psychiatrists Association (BPPA) and All Pakistan Physician Association of Northern Europe (APPNE) on Friday the 1st October 2021

Curriculum Vitae
Mujeeb U. Shad, M.D., M.S.C.S

“What is New in Psychopharmacology for the Primary Care Physicians to Know,” presented at the 32nd Annual Summer Meeting of the Nevada Association for Family Practitioners (NAFP), Tropicana, Las Vegas, July 29 – August 1, 2021.

“What is New in Psychopharmacology for the Primary Care Physicians to Know,” presented at the 32nd Annual Summer Meeting of the Nevada Association for Family Practitioners (NAFP), Tropicana, Las Vegas, July 29 – August 1, 2021.

"An Update on Psychopharmacology," presented at the **3rd Annual Adult Mental Health Update: Strategies for Primary Care,** on March 15, 2019, for Oregon Health & Science University in Portland, Oregon.

Adult Alternative Treatments for Major Depression: Glabellar Botulinum Toxin Injections. Grand round presented at the Good Samaritan Healthcare System, January 4, 2019.

Pharmacogenetics & Pharmacogenomics of Psychotropic Medications: Basic Concepts. Presented at the April Summit meeting of the National Alliance of Healthcare Purchasers Coalitions in Denver on April 24, 2017.

Pharmacogenomics of Psychotropic Medications. Presented at the Annual Meeting of Oregon Guardian and Conservators Association in Eugene OR May 2017.

Drug-Drug Interactions and their Clinical Relevance. Presented at Oregon Health & Science University Primary Care Review Conference; Portland, Oregon on February 11, 2016.

Curriculum Vitae
Mujeeb U. Shad, M.D., M.S.C.S

Drug-Drug Interactions and their Clinical Relevance. Grand Round presented at Oregon Health & Science University Primary Care Review Conference; Portland, Oregon, on February 11, 2016.

Drug-Drug Interactions and their Clinical Relevance. Grand Round presented at Oregon Health & Science University, Portland, Oregon, on November 17, 2015.

Drug-Drug Interactions and their Clinical Relevance. Grand Round presented at Oregon Health & Science University, Portland, Oregon, on November 17, 2015.

Pharmacogenomics of Psychotropic Medications: The Good, the Bad, the Ugly Part I, presented at the Annual Winter Meeting of Oregon Physician Psychiatrist Association on February 27, 2015, in Portland.

Pharmacogenomics of Psychotropic Medications: The Good, the Bad, the Ugly Part II, presented at the Annual Winter Meeting of Oregon Physician Psychiatrist Association on February 28, 2015, in Portland.

Stress Management: A focus on Self-Assessment. Presented at the Willamette Humane Society, Salem, Oregon, on January 19, 2015.

Trauma Response Management for Certified Euthanasia Technician (C.E.T.). Presented at the Willamette Humane Society, Salem, Oregon, on January 19, 2015.

Neurobiology of Self-Awareness in Schizophrenia. CME presentation at the annual Sindh Medical College Retreat in New York on March 31, 2012.

Curriculum Vitae
Mujeeb U. Shad, M.D., M.S.C.S

Presented "**Omega 3 Polyunsaturated Fatty Acids: Epigenetics and Brain Function**" in a seminar at the annual meeting of American Psychiatric Association (APA) meeting in New York 2014 in May 2014.

Neurobiology of Self-Awareness in Schizophrenia. **Grand Rounds** at the University of Texas Health Science Center at Houston on November 9, 2011.

Neurobiology of Insight Deficits in Schizophrenia. **Grand Rounds** at the University of Texas Southwestern at Dallas on January 28, 2009.

Drug-Drug Interactions and their Clinical Relevance in Elderly Subjects. Presentation for the geriatric fellows on February 12, 2008, at UT Southwestern Medical Center at Dallas.

Neurobiology of Insight Deficits in Schizophrenia. **Grand Rounds** at Dallas VAMC on January 17, 2008.

Cognitive Deficits in Schizophrenia. Presentation for the fellows on January 15, 2008, at UT Southwestern Medical Center at Dallas.

Cognitive Deficits in Schizophrenia. **Grand Rounds** at University of Kansas School of Medicine-Wichita on May 8, 2007.

Dissociative Disorders and Schizophrenia. Presentation for senior MSW students at Texas A&M University, Mesquite Campus, on July 11, 2005.

Cognitive Deficits in Schizophrenia and Their Treatment. Grand Rounds for the Department of Psychiatry at JPS. Health Network, Fort Worth, Texas May 13, 2005.

Curriculum Vitae
Mujeeb U. Shad, M.D., M.S.C.S

*Drug-Drug Interactions and Their Clinical Relevance. **Grand Rounds*** at Metrohealth Medical Center, Cleveland, OH on October 9, 2003.

*Selecting an Ideal Antidepressant for the Patients. **Grand Rounds*** at the medicine department at the Buffalo VAMC, University of Buffalo, SUNY on April 17, 2003.

*Best Practices in the Treatment of Anxiety Disorders. **Grand Rounds*** at University of Pittsburgh Medical Center, Passavant, Pennsylvania on March 4, 2003.

*A Comparative Analysis of SSRIs. **Grand Rounds*** at Metrohealth Medical Center, Cleveland, OH on February 20, 2003.

*SSRIs and Their STEPS. **Grand Rounds*** at Meadville Medical Center, Meadville, PA on April 24, 2002.

*Atypical Antipsychotics and Their STEPS. **Grand Rounds*** at Brecksville Veteran's Administration Medical Center OH on April 13, 2002.

*Clinical and Economical Consequences of Polypharmacy. **Grand Rounds*** at Case Western Reserve University, Cleveland, OH on April 12, 2002.

*Atypical Antipsychotics and Their STEPS. **Grand Rounds*** at Northcoast Behavioral Healthcare Northfield Campus, Cleveland OH on April 12, 2002.

A videoconference for Warren State Hospital, PA "*Metabolism of Psychotropic and Other Medications.*" Presented on February 12, 2002, sponsored by the *Office of Education and Regional Programming (OERP)* at Western Psychiatric Institute and Clinic.

Curriculum Vitae
Mujeeb U. Shad, M.D., M.S.C.S

An Update in the Treatment of Schizophrenia. **Grand Rounds** at Beaver Medical Center, Beaver, PA, presented on January 11, 2002.

An Update on Atypical Antipsychotics. **Grand Rounds** presented at Mansour Medical Center, McKeesport, PA, on August 6, 2001.

Mood Disorders in the Elderly. **Grand Rounds** presented at the Washington Hospital, Washington, PA, on July 25, 2001.

Update on Atypical Antipsychotic Medications. Presented for the Westmoreland County Primary Health Center, Greensburg, PA, on June 23, 2001.

Update on Atypical Antipsychotic Medications. Presented at Jefferson Behavioral Center, Steubenville, OH, on May 25, 2001.

Update on Atypical Antipsychotic Medications. Presented to Westmoreland Primary Health Center for the Primary Care Physicians at Greensburg, PA, on May 23, 2001.

Atypical Antipsychotics and their STEPS. **Grand Rounds** presented at St. Francis Regional Medical Center, Pittsburgh, PA, on April 5, 2001.

SSRIs and their STEPS (safety, tolerability, efficacy, payment, and simplicity). **Grand Rounds** for Weirton Medical Center at Weirton WV on February 6, 2001.

Drug Interactions of Psychotropic Medications and Their Clinical Impact. **Grand Rounds** for Allegheny General Hospital in Pittsburgh, PA, on February 8, 2001.

Update on Atypical Antipsychotics. **Grand Rounds** presented at Torrance State Hospital, Torrance, PA, on March 21, 2001.

Curriculum Vitae
Mujeeb U. Shad, M.D., M.S.C.S

"Atypical Antipsychotics and Their STEPS (Safety, Tolerability, Efficacy, Price, and Simplicity). **Grand Rounds** presented at Highland Veteran's Administration Hospital, Pittsburgh, PA, on November 30, 2000.

Atypical Antipsychotics and their STEPS (Safety, Tolerability, Efficacy, Price, and Simplicity). **Grand Rounds** at University of Kansas School of Medicine-Wichita on May 23, 2000.

SSRIs and their STEPS (Safety, Tolerability, Efficacy, Price, and Simplicity). Presented to the graduating nursing practitioners at Wichita State University on April 12, 2000.

"Current Management Strategies for Mood and Anxiety Disorders in Primary Care Setting," Presented to Primary Care Physicians on December 21, 1999, in Wichita, KS, sponsored by Pfizer Pharmaceuticals.

"Safety, Tolerability and Efficacy of Newer Antidepressants." Presented to the psychiatry residents on December 8, 1999, at Western Missouri Mental Health Center, Kansas City, MO, sponsored by Wyeth-Ayerst.

"Safety, Tolerability and Efficacy of Newer Antidepressants." Presentation on December 8, 1999, at VAMC, Kansas City, MO, sponsored by Wyeth-Ayerst.

"Current Management Strategies for Mood and Anxiety Disorders in the Psychiatric Setting." Presented to Psychiatrists on October 21, 1999, in Kansas City, MO, sponsored by Pfizer Pharmaceuticals.

Curriculum Vitae

Mujeeb U. Shad, M.D., M.S.C.S

"SSRIs and their STEPS (Safety, Tolerability, Efficacy, Price, and Simplicity)," **Grand Rounds** at Medical College of Georgia, Augusta on September 30, 1999, sponsored by Pfizer Pharmaceuticals.

"Current Management Strategies for Mood and Anxiety Disorders in the Psychiatric Setting," presented to Psychiatrists on September 14, 1999, in Kansas City, MO, sponsored by Pfizer Pharmaceuticals.

"Antipsychotics and Re-Hospitalization," presented at Larned State Hospital, Larned, KS, July 21, 1999, sponsored by Janssen Pharmaceutical.

"Prevalence of Depression and Its Treatment in Myocardial Infarction," presented at the 30th Annual Cardiovascular Nursing Seminar of American Heart Association in Wichita on March 12, 1999, sponsored by Pfizer Pharmaceuticals.

"Treatment of Bipolar Disorders," presented to psychiatry residents at Griffin Memorial Hospital, Norman, OK, March 4, 1999, sponsored by Janssen Pharmaceutical as part of the Visiting Faculty Program.

"Comparison and Contrast of Classes of Antidepressants and their Indications," presented to the nursing staff at Hutchinson Hospital, Hutchinson, KS, December 11, 1998.

"Venlafaxine and Drug-Drug Interactions" presented in Wichita, KS; October 27, 1998, sponsored by Wyeth-Ayerst as part of the Visiting Professor Program.

"Pharmacoeconomics of Depression," presented at Adam's Mark Hotel in Kansas City, MO, October 26, 1998, for Theracom sponsored by Pfizer.

Curriculum Vitae
Mujeeb U. Shad, M.D., M.S.C.S

"Antipsychotic Medications," presented to nursing students at Wichita State University, Wichita, KS, October 23, 1998.

"Schizophrenia Update," presented at Crawford-Cherokee County Medical Society Meeting, Pittsburg, KS, July 23, 1998, sponsored by Janssen Pharmaceutical.

"Atypical Antipsychotics," presented at Larned State Hospital, Larned, KS, June 12, 1998, sponsored by Janssen Pharmaceutical.

"Antidepressants and Sexual Dysfunctions," presented to Ob/Gyn residents at Wesley Hospital, Wichita, KS, March 25, 1998, sponsored by Bristol-Myers Squibb.

"The Mechanisms of Action of Newer Antidepressants," presented to Smoky Hill Family Practice residents and faculty, Salina, KS, March 20, 1998, sponsored by Bristol-Myers Squibb.

"Mechanisms of Action of Newer Antidepressants," presented in Wichita, KS, July 12, 1997, as part of Visiting Professor Program sponsored by Wyeth-Ayerst.

INTERNATIONAL PRESENTATIONS:

"Neurobiological Effects of COVID-19 in the Geriatric Population" virtually presented at the meeting titled "COVID-19 and its Long-Term Impact on Mental Health Care and Learning, What Lessons Can Be learnt?" by the for the World Association for Psychosocial Rehabilitation – WAPR-UK with Pennine Care NHS Foundation Trust (PCFT), British Pakistani Psychiatrists Association (BPPA) and All Pakistan Physician Association of Northern Europe (APPNE) on Friday the 1st October 2021

Curriculum Vitae
Mujeeb U. Shad, M.D., M.S.C.S

"What is New in Psychopharmacology for the Clinicians to Know? Recorded on July 15, 2021, presented virtually at the World Psychiatric Association meeting in Lahore on July 30, 2021.

"Telepsychiatry and Problem-Based Learning in Psychopharmacology." A British Pakistani Psychiatrists Association web conference on "Digital Technology for Mental Health Needs in Pakistan. January 30, 2021.

"A series of 10 lectures and workshops on various psychopharmacological and neuroimaging topics." An APPNA-MERIT sponsored visit funded by WHO to the Dow University of Health Sciences (DUHS) and Sindh Medical College, Karachi, Pakistan, from 18th to December 31, 2010.

"Cognitive Deficits and the Pharmacological Treatment of Insight Deficits in Schizophrenia." An APPNA-MERIT (Psychiatry MERITnet) presentation during the annual summer meeting of the Association of Physicians of Pakistani-Descent in North America (APPNA) at Dallas telecasted to 12 major universities in Pakistan, July 1, 2010.

"Cognitive Deficits in Schizophrenia: Novel Targets for Treatment." A CME presentation for 17th International Psychiatric Conference at the biannual meeting of Pakistan Psychiatric Society [in association with World Psychiatric Association (WPA) in Quetta, Pakistan on November 30, 2008.

"Recent Advances in the Treatment of Depression." Presented at the Dow University of Health Sciences, Karachi, Pakistan, on November 25, 2008.

Curriculum Vitae

Mujeeb U. Shad, M.D., M.S.C.S

"Cognitive Deficits in Schizophrenia: Novel Targets for Treatment." A CME presentation for International Seminar on Psychiatry at the annual meeting of Midlands Psychiatric Research Group [in association with World Psychiatric Association (WPA) and World Association for Psychosocial Rehabilitation (WAPR) at Birmingham N.E.C., the United Kingdom on June 27, 2008.

Chaired the opposition committee for a Ph.D. thesis titled, "Insight in Bipolar I Disorder: Neurocognitive, Neurobiological, and Psychopathological Correlates," by Monica Varga at the Department of Psychology, Faculty of Social Sciences, University of Oslo, Norway in April 2008.

Neurobiology of Insight Deficits in Schizophrenia. ***A Plenary Session at the First World Congress in Asian Psychiatry***, Goa India, on August 3, 2007.

"New Advances in Psychopharmacology of Schizophrenia and Depression." Presented at the Jinnah Post Graduate Medical Center, Karachi, Pakistan, on February 3, 2003.

"Drug-Drug Interactions and Their Clinical Relevance." Presented at Services Hospital in Islamabad, Pakistan, on March 15, 2001.

A *"Workshop on Depression"* was presented at the Pakistan Institute of Medical Sciences (PIMS) in Islamabad on March 14, 2001.

"Introduction to Designs and Methods in Psychopharmacological Research and Standards Set by FDA to Approve New Drug Applications." Presented at Polyclinic in Islamabad, Pakistan, on March 13, 2001.

A 10-day seminar titled ***"The Advances in Psychopharmacological Research and its Impact in Treating Psychiatric Illnesses,"*** including different lectures on

Curriculum Vitae
Mujeeb U. Shad, M.D., M.S.C.S

pathophysiology, diagnosis, and treatment of depression and schizophrenia, herbal treatment of psychiatric illnesses, drug-drug interactions, gender differences in depression and its treatment, and research methodologies. Presented at the HEJ Department of Chemistry, University of Karachi, Pakistan from February 19 to 28, 2001 **TOKTEN** (*Transfer of Knowledge through Talented Expatriate Nationals*), a program sponsored by **United Nations Development Funds**.

"Recognition and Treatment of Depression in Women" and "Drug-Drug Interactions." Presented at HEJ Research Institute of Chemistry, University of Karachi, Karachi-75270 Pakistan on February 3, 2000.

"Antidepressants and Drug-Drug Interactions." Presented at the World Regional Congress of Biological Psychiatry, III Latin American Congress of Biological Psychiatry, V Brazilian Congress of Biological Psychiatry, Sao Paulo, Brazil on April 30, 1998.

"Premenstrual Syndrome and SSRIs." Presented at Sobhraj Women's Hospital in Karachi, Pakistan, December 1996.

"Pharmacotherapy for the Major Depressive Disorder and Selection of an Antidepressant." Presented at the Karachi Branch of Pakistan Medical Association, December 1996.

AWARDS AND RECOGNITIONS ACHIEVEMENTS:

Distinguished Fellow of the American Psychiatric Association; January 1, 2022.

Distinguished Recognition for Excellence in Medical School Education 2017.
Received from the Oregon Health & Science University School of Medicine.

Curriculum Vitae
Mujeeb U. Shad, M.D., M.S.C.S

Received "**Best Teacher of the Year Award**" by the PGY 3 residents at the Good Samaritan psychiatry residency program, June 2017.

Fellow of the American Psychiatric Association; December 15, 2015.

Awarded **Research Committee Recognition of Aptitude** Certificate at Oregon State Hospital in July 2105.

Awarded "**2011-2012 Dean's Teaching Excellence Award**" April 16, 2012.

Awarded "**Outstanding Teacher Award 2011**" by the third-year psychiatry residents on June 17 2011.

Awarded K23 (NIH Mentored Research Development Award # 5K23MH077924-02) for the application titled "**Neurobiology of Insight Deficits in Schizophrenia,**" on February 1, 2008.

Received **K-30 Training Award** in the Clinical Scholars Track to sponsor tuition for **Masters in Clinical Sciences and Research** funded by NIH at University of Texas Southwestern Medical School at Dallas in 2004.

Awarded **Clinical Scholars Track** at the University of Texas Southwestern Medical School at Dallas in August 2004.

Life Member of National Registry of Who is Who, Publication: 2001- Edition of National Registry of Who is Who (# 141564).

Curriculum Vitae
Mujeeb U. Shad, M.D., M.S.C.S

Award for **Academic Excellence** from Sind Medical Alumni Association of North America (SMCAANA) at the Annual Meeting of Association of Pakistani Physicians of North American (APPNA) at Chicago, IL on July 6, 2001

Awarded "**Psychiatrist of the Year 2001**" at the annual banquet of Comprehensive Care Department of Western Psychiatric Institute and Clinic on November 15, 2001.

First position in the **Young Investigator Award Competition** at the annual meeting of the **Association of Pakistani Physicians of North America (APPNA)** in 1999 in New Orleans, LA.

Certificate of Recognition from the **National Alliance for the Mentally Ill (NAMI), Wichita**, for outstanding dedication and continued support of mentally ill loved ones, December 1999.

Janssen Research Award for outstanding accomplishments in psychiatric research 1997-1998.

Resident's Paper Award of the **Central Neuropsychiatric Association**, 1997.

Annual Award for outstanding contributions to help the mentally ill from the **National Alliance for the Mentally Ill (NAMI), Wichita** 1997.

Awarded R25 (**Junior Faculty Scholars Program**) sponsored by National Institute of Mental Health.

Upjohn Research Award, 1996-97.

Curriculum Vitae
Mujeeb U. Shad, M.D., M.S.C.S

Received **Baumhardt award**, May 1997 on a paper titled "The potential for drug-drug interactions with older versus newer antipsychotic medications."

Upjohn Research Award for outstanding accomplishments in psychiatric research 1996-1997.

MEDICAL

Nevada Medical License # 2009 (issued June 30 2020) Expiration 06/30/2021

Oregon Medical License # MD164839 (issued 12/30/2013) Expiration 12/31/2021

Illinois # 036-132238 (issued April 3, 2013)

Expired

Texas # M3732 (Issued June 2, 2006)

Expiration 2/28/2022.

Pennsylvania # MD-070604-L (Issued: May 18, 2000).

No Expiration.

Kansas # 04-25741 (Status: inactive; Issued: June 23, 1995). Expired 6/30/2013.

California #A101642 (Issued September 26 2007). Expiration 9/30/2021.

Pakistan Medical and Dental Council (PMDC #7141S)

August 1983.

Curriculum Vitae
Mujeeb U. Shad, M.D., M.S.C.S

DEA REGISTRATION:

DEA Registration # 336.093542 (Issued 3rd April 2013 Expiration = 07/31/2018).

DEA # FS3782768 (Issued 9th April 2013; Schedule 2, 2N, 3, 3N, 4, 5. Expiration = 02-29-2018)

BOARD CERTIFICATION:

General Psychiatry:

Certified in **Psychiatry** by the American Board of Psychiatry and Neurology (ABPN Certificate # 55732, January 1, 2006, San Francisco CA). Recertification 2/2026.

Preventive Medicine:

Certified by the **American Board of Preventive Medicine** (ABPM ID: 61-3148). **ABPM ID:** ABPM-GJHJC-T3148; **NPI:** 1871519041 Board Certification: Addiction Medicine Valid: 1/1/2018 - 1/31/2028.

Advanced Psychopharmacology:

Certified in **Advanced Psychopharmacology** by the American Society for Clinical Psychopharmacology (ASCP); May 19, 2007, in San Diego, CA.

COMMUNITY

SERVICE:

Curriculum Vitae

Mujeeb U. Shad, M.D., M.S.C.S

January 1996 - June 2000 Attended monthly "Share and Care" meetings of the Alliance for the Mentally ILL (NAMI)

July 1995 - September 1995 Psychiatric Consultation for terminally ill patients at Hospice.

PROFESSIONAL COMMITTEE SERVICES

Continue to serve as **MOC liaison** for **American Society of Psychopharmacology** since **2018**.

President, **Pakistani American Psychiatrist Association of North America (PAPANA)** since July 2020.

Member of the American Society of Clinical Psychopharmacology curriculum committees for medical students and Primary Care and Psychiatry Residents since **2015**.

Appointed **Chair of the ASCP curriculum sub-committee on "Innovations in Psychopharmacology Teaching"** since June 2019.

CONSULTANT/SUPERVISOR

Appointed Chair of the ASCP curriculum sub-committee on "Innovations in Psychopharmacology Teaching" since June 2019.

Curriculum Vitae

Mujeeb U. Shad, M.D., M.S.C.S

Mentor for the New Investigator Award (NIA.) Program at the annual meeting of the American Society for Clinical Psychopharmacology 2016 May 30 to June 2nd 2017, in Miami Beach, FL.

Mentor for a junior investigator at the Society of Biological Psychiatry's Annual Meeting in San Diego, May 2017.

Mentor for the New Investigator Award (NIA.) Program at the annual meeting of the American Society for Clinical Psychopharmacology 2016 May 30 to June 3, 2016, in Phoenix, AZ.

Member of American Society of Psychopharmacology Curriculum Committees for Residents and Medical Students since 07/10/2015.

Mentor for a junior investigator at the Society of Biological Psychiatry's Annual Meeting in Atlanta, May 2016.

Member of the advisory committee for a Ph.D. dissertation titled, "DUAL MODELS OF DECISION MAKING: AN FMRI INVESTIGATION OF FRAMING EFFECTS AND INDIVIDUAL DIFFERENCES," by Kevin B. Murch presented to the faculty of the Graduate School of Biomedical Sciences, The University of Texas Southwestern Medical Center, Dallas, TX in December 2009.

Chaired the opposition committee for a Ph.D. thesis titled, "Insight in Bipolar I Disorder: Neurocognitive, Neurobiological, and Psychopathological Correlates," by Monica Varga at the Department of Psychology, Faculty of Social Sciences, University of Oslo, Norway in April 2008.

Curriculum Vitae
Mujeeb U. Shad, M.D., M.S.C.S

TEACHING ACTIVITIES:

February 2021 – March 2021

Didactics for Family Practice Residents, Valley Health System Family Practice Residency Program, Las Vegas, NV.

Four lectures for a crash course in psychopharmacology.

April 2021.

Didactics for PGY-3 Psychiatry Residents, University of Nevada, Las Vegas, NV.

2 two hour lectures on pharmacogenomics of psychotropic medications.

March 2014 – Nov 2019

Didactics for medical students, psychiatry residents, and other trainees at the Oregon State Hospital from Oregon Health & Science University (OHSU.) Portland Oregon.

Weekly psychopharmacology seminar primarily on antidepressant and antipsychotics with focus on pharmacodynamics and pharmacokinetics along with a discussion of drug-drug interactions and neurobiological aspects of pharmacotherapy using a translational neuroscience approach

Weekly Journal Club with emphasis on original research papers and their methodology in an effort to induce critical thinking.

Curriculum Vitae
Mujeeb U. Shad, M.D., M.S.C.S

Developing research writing skills with the help of writing case reports, case studies, and reviews.

March 2016 – Jan 2020

Clinical and Research Supervisor for psychiatry residents and medical students at the Samaritan Mental Healthcare psychiatry residency program Corvallis, Oregon.

Formulated a research curriculum for residents to be implemented starting with PGY 1 in July 2019

Weekly psychopharmacology seminar primarily on antidepressant and antipsychotics with focus on pharmacodynamics and pharmacokinetics along with a discussion of drug-drug interactions and neurobiological aspects of pharmacotherapy using a translational neuroscience approach

Monthly Journal Club with emphasis on original research papers and their methodology to induce critical thinking.

Supervisor for writing and submitting a quality improvement project with using ketamine infusions in acute suicidality assessed with Columbia Scale for Suicidal Risk in emergency department.

Developing research writing skills with the help of writing abstracts, case reports, case studies, and reviews.

Curriculum Vitae
Mujeeb U. Shad, M.D., M.S.C.S

March 2014 – August 2017

Director for PGY 2 residents training at Oregon State Hospital (OSH), Salem, Oregon) from Oregon Health & Science University (OHSU.) Portland Oregon.

Managing and coordinating administrative, training, and educational aspects of residents' training for 8 OHSU. psychiatry residents (PGY 2) rotating at OSH for their three months forensic and geriatric rotations.

Weekly psychopharmacology seminar primarily on antidepressant and antipsychotics with focus on pharmacodynamics and pharmacokinetics along with a discussion of drug-drug interactions and neurobiological aspects of pharmacotherapy using a translational neuroscience approach for Psychiatry residents PGY 2 from Oregon Health Science University Portland Oregon; PGY 3 Psychiatry Residents; Good Samaritan DO program in Corvallis Oregon; Physician Assistant Students; Oregon Health Science University, Portland Oregon; Pharmacy Students; Training program at the Oregon State Hospital; Geriatric Medicine Fellows; Oregon Health Science University, Portland Oregon; Geropsychiatry Fellows; Geriatric Medicine Fellows from Oregon Health Science University, Portland Oregon.

Weekly Journal Club with emphasis on original research papers and their methodology to induce critical thinking for:

Psychiatry residents P.G.Y. 2 from Oregon Health Science University Portland Oregon; P.G.Y. 3 Psychiatry Residents; Good Samaritan DO program in Corvallis Oregon; Physician Assistant Students; Oregon Health Science University, Portland Oregon; Geriatric Medicine Fellows; Oregon Health Science University, Portland Oregon; Geropsychiatry Fellows; Geriatric Medicine Fellows from Oregon Health Science University, Portland Oregon.

Curriculum Vitae
Mujeeb U. Shad, M.D., M.S.C.S

Chair, Graduate Medical Education Committee, Oregon State Hospital; Salem, Oregon.

March 2013 – Sept. 2013

Southern Illinois University Springfield Illinois (Program Director Residency Training Program)

Managing and coordinating all administrative, training, and educational aspects of residents' training for four categorical residents and two med-Psych combined program residents each year.

PGY 2 & 3: Supervising outpatient residents' clinics (both medication management and psychotherapy clinics).

PGY 1: Seminar on emergency psychiatry.

PGY1, 2 &3: Psychopharmacology seminars with Introduction to Pharmacology: Neurotransmitters and Receptors.

Psychopharmacology of affective and psychotic disorders with the following specific topics:

- a. Lectures on how to enhance treatment adherence in the psychiatric population.
- b. Drug-drug interactions and their clinical relevance in psychiatry.
- c. Neurostimulation in affective disorders.

Curriculum Vitae
Mujeeb U. Shad, M.D., M.S.C.S

d. Novel strategies to enhance cognition in schizophrenia.

P.G.Y. 3 & 4: Neuroscience Seminar.

PGY 3 & 4: Seminar on neuroimaging, focus on fMRI. Application of neuroimaging in Psychiatric research and its clinical implications.

All PGY: Conducting Journal Club and Research Seminars.

All PGY: Coordinating and mentoring residents on research projects.

Mentored a senior resident to receive the 2013 Janssen Academic Research Mentorship (ARM.) Program Award.

University of Texas Health Sciences Center Medical School at Houston

MS III: Supervision of MS III at the university outpatient psychiatry clinic.

MS II: Three lectures on:

1. Prevalence, diagnosis, and phenomenology of schizophrenia (2 hours).
2. Neurobiology, differential diagnosis and risk factors for of schizophrenia (1 hour)
3. Antipsychotic treatment for schizophrenia (1 hour).

Curriculum Vitae
Mujeeb U. Shad, M.D., M.S.C.S

PGY3: Supervision of third-year residents at the outpatient psychiatry clinic.

Awarded 'Outstanding Teacher's Award' on June 17, 2011.

PGY1: Lecture on Introduction to Pharmacology: Neurotransmitters and Receptors.

PGY4 Lectures:

1. Lectures on how to enhance treatment adherence in a psychiatric population.
2. Drug-drug interactions and their clinical relevance in psychiatry.
3. Neurostimulation in affective disorders.
4. Novel strategies to enhance cognition in schizophrenia.

University of Texas Southwestern Medical Center at Dallas

Geriatric Fellows: Lectures on cognitive deficits in schizophrenia
Lecture on the clinical relevance of drug-drug interactions

PGY4: Lecturer for the Neuroscience Course focusing on neuroimaging in schizophrenia

PGY3: Teach APA guidelines for schizophrenia

Curriculum Vitae
Mujeeb U. Shad, M.D., M.S.C.S

PGY2: Lectures during inpatient rotations

Lecturer in PGY2 lecture series

PGY1: Lectures on translational aspects of schizophrenia research and application to real life practices during inpatient rotations

Lecturer in PGY1 lecture series

Medical students: Attending for MS3's on ACCESS team during their rotation in general psychiatry at Dallas VAMC.

Attending for MS3's on their inpatient rotations at Zale Lipshy Hospital.

Mentored students from STARS and E Conrad Scholarship programs in neuroimaging research projects.

2000-2004

**Western Psychiatric Institute and Clinics at University of Pittsburgh
Medical Center, Pittsburgh PA.**

PGY3: As a Director of Comprehensive Care Outpatient Services, supervised PGY3 Residents during their outpatient rotations.

Awarded "***Psychiatrist of the Year 2001***" at the annual banquet of comprehensive Care

Curriculum Vitae
Mujeeb U. Shad, M.D., M.S.C.S

Department of Western Psychiatric Institute and Clinic on November 15, 2001.

PGY2: Directed Inpatient Psychiatry Case Conferences.

PGY1: Supervision during their inpatient rotations.

Medical students:

Conducted daily lectures in General Psychiatry to third-year medical students.

University of Kansas School of Medicine Wichita, KS.

PGY3: As a Director of Resident's Outpatient clinic, supervised residents daily during their outpatient rotations.

PGY2: Directed Inpatient Psychiatry Case Conferences

PGY1: Supervised residents during their inpatient rotations.

Medical students:

Conducted lectures in General Psychiatry to third-year medical students

ADVISORY MEETINGS:

Attended National Network of Psychiatric Educators (NNPE) meeting sponsored by Bristol Myers-Squibb Orlando, FL from 14th to April 16, 2005.

Curriculum Vitae
Mujeeb U. Shad, M.D., M.S.C.S

Attended National Network of Psychiatric Educators (NNPE) meeting sponsored by Bristol Myers-Squibb Orlando, FL from 20th to November 23, 2003.

Attended Janssen Speaker's Training Program in Pittsburgh, PA, on October 4, 2003.

Attended Janssen Advisory Board Meeting in Chicago on September 12th and 13th, 2003.

Attended Pfizer's Regional Consultant Initiative in Cleveland, Ohio, on September 10, 2000.

Attended National Psychiatry Speakers Alliance sponsored by Pfizer Pharmaceuticals in Washington, D.C., May 14, 1999.

Attended CNS. Primary Care Advisory Board Meeting sponsored by Wyeth Ayerst in Tampa, FL, April 23-25, 1999.

Attended Janssen Leadership Development Forum in New Orleans, LA, on November 5 and 6, 1999.

Attended Neuroscience Visiting Faculty Conference for Psychiatrists sponsored by Bristol-Myers Squibb in Las Croabas, Puerto Rico, January 21-24, 1999.

Attended National Psychiatry Speakers Alliance sponsored by Pfizer Pharmaceuticals in San Diego, CA, May 16, 1997.

Curriculum Vitae
Mujeeb U. Shad, M.D., M.S.C.S

Attended Psychoses '97 as a member of the Educational Advisory Panel sponsored by Janssen Pharmaceuticals at Universal City, CA on February 21-23, 1997.

CME MANAGEMENT:

Chairman C.M.E. committee, at the annual meeting of Sindh Medical College Alumni Association of North America (SMCAANA) at New Orleans, LA in 1999.

Chair, Graduate Medical Education Committee at Oregon State Hospital; 2015 to 2018.

Graduate Medical Education Committee at Napa State Hospital; 2020.

EDITORIAL BOARDS

1. Frontiers in Neuropsychiatric Imaging and Stimulation
2. Journal of Translational Neuroscience
3. Sensory System Journal
4. Current Psychiatry Research and Reviews

Reviewer for Maintenance of Certification (M.O.C.) Liaison (CME MCQs) from June 2017 to May 31, 2020

Curriculum Vitae
Mujeeb U. Shad, M.D., M.S.C.S

Reviewer For the NIMH Committees

ZRG1 BDCN N 03 M Meeting Date: 7/29/2010

Reviewer for Journals

- i. American Journal of Psychiatry
- ii. Molecular Psychiatry
- iii. The Annals of Pharmacotherapy
- iv. Journal of Clinical Psychopharmacology
- v. Bipolar Disorders
- vi. International Journal of Geriatric Psychiatry
- vii. Drug Safety
- viii. Progress in Neuro-Psychopharmacology and Biological Psychiatry

- ix. Journal of Affective Disorders
- x. Israel Journal of Psychiatry
- xi. Primary Psychiatry
- xii. CNS. Spectrums
- xiii. Psychiatry Research
- xiv. Asian Journal of Psychiatry
- xv. Cognitive Neuropsychiatry
- xvi. Journal of Children and Adolescent Psychopharmacology
- xvii. Schizophrenia Research
- xviii. Schizophrenia Bulletin
- xix. PLOS ONE
- xx. Expert Systems with Application

Curriculum Vitae
Mujeeb U. Shad, M.D., M.S.C.S

RESEARCH EXPERIENCE:

Principal Investigator:

A new research project, titled, Relationship between smoking and rehospitalization in clozapine-treated patients with schizophrenia, submitted to the research committee at Oregon State Hospital, followed by IRB approval from OHSU.

Utility of a Pharmacogenomic Algorithm for Psychotropic Medications. An investigator-initiated grant from Admera Inc.; 2019-2021.

Investigator-initiated trial approved by Neurocrine pharmaceutical investigating augmentation with a new psychotropic medication valbenazine in schizophrenia patients. Tring to initiate at Samaritan Mental Healthcare system.

Utility of a Pharmacogenomic Algorithm for Antipsychotic Medications. An investigator-initiated grant from Assurex Health (GeneSight); October 2015.

Minocycline Augmentation in Early-Course Schizophrenia. Grant Supported by Stanley Medical Research Institute (Stanley Foundation) for three years starting 2012.

Neurobiology of Insight Deficits in Schizophrenia (as the research project for the K-23 award). Completed in July 2012.

Impact of Olanzapine on Insight in Schizophrenia (Investigator-initiated trial funded by Lilly Pharmaceutical Inc). Completed in 2012.

Curriculum Vitae
Mujeeb U. Shad, M.D., M.S.C.S

Structural Correlates of Insight in Bipolar Subjects (funded through MIRECC/VISN 4).
Completed in 2012.

Insight and Neurocognitive Functioning in Bipolar Subjects (funded through
MIRECC/VISN 4). Completed 2011.

CO/SUB-INVESTIGATOR:

- Paroxetine in the treatment of depression.
- Ziprasidone in the treatment of schizophrenia.
- Mirtazapine in the treatment of depression.
- Risperidone, a two-year study of maintenance treatment in schizophrenia.
- Reboxetine in the treatment of depression.
- Flibanserin in the treatment of depression.
- Selegiline dermal patch in the treatment of depression.
- Buspirone dermal patch in the treatment of ADHD.
- Venlafaxine in the treatment of GAD.
- Venlafaxine study to examine its dual mechanism of action.
- Nefazodone treatment for depression in children.
- Sertraline in the treatment of PMDD.
- Propentofylline in the treatment of Alzheimer's dementia.
- Aripiprazole in the treatment of schizophrenia.
- M-100907 in the treatment of schizophrenia.
- Iloperidone in the treatment of schizophrenia.
- CP 361 in the treatment of schizophrenia.
- MK- 0869 in the treatment of depression.
- L-795274 for melancholic depression.
- CP 409, 092 in the treatment of GAD.

Curriculum Vitae

Mujeeb U. Shad, M.D., M.S.C.S

- Novartis 141 in the treatment of depression.
- Novartis 107 for social phobia.
- Risperidone-donepezil interaction study.
- Nefazodone ER in the treatment of depression.
- Venlafaxine ER: Effects on EKG.
- Venlafaxine ER versus sertraline (efficacy in depression).
- DAB-452 in the treatment of schizophrenia.
- L-759274 in the treatment of melancholic depression.
- Estrogen plus donepezil in the treatment of Alzheimer's dementia).
- Bioavailability of buspirone patch in the treatment of GAD.
- Aripiprazole versus haloperidol in the treatment of schizophrenia.
- Venlafaxine ER in the treatment of childhood and adolescent depression.
- Citalopram in the treatment of childhood and adolescent depression.
- Olanzapine/risperidone cross-over study for the treatment of weight gain.
- Effect of olanzapine delta sleep study
- Olanzapine in the treatment of schizotypal personality disorder.
- Systematic Treatment Enhancement Program-Bipolar Disorder (STEP-BD).
- Comorbidity survey in VA bipolar subjects
- fMRI study of cognitive remediation and/or atomoxetine trial to enhance cognition in schizophrenia

EXTRACURRICULAR

Chairman Election Commission for Sind Medical College Alumni Association of North America (SMCAANA) in 2000.

Social Secretary of the Doctors' Association of Lyari General Hospital Karachi for a year, 1985-86

Curriculum Vitae
Mujeeb U. Shad, M.D., M.S.C.S

Social Secretary of the Residents' Association for a year, 1983

Served as an elected "Social Secretary" of the Sind Medical College Students' Union for two consecutive years, 1981-82

HOBBIES:

Organization of social and cultural activities

Singing, playing the keyboard, and listening to music

Performing traditional semi-classical Indian sub-continent (Pakistani/Indian) music as a vocalist and musician in various major cities of North America

Reading and writing poetry

REFERENCES: On request